WORCESTER, Mass., Oct. 23, 2008 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (http://www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that the Nasdaq Listing Qualifications Panel has extended until April 27, 2009 the time that the Company has to regain compliance with the $1.00 minimum bid price for continued listing as required in Marketplace Rule 4310(c)(4). The Company previously had until January 20, 2009.
